好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Anti-Hu Limbic Encephalitis Induced by Checkpoint Inhibitor
Autoimmune Neurology
P11 - Poster Session 11 (11:45 AM-12:45 PM)
1-012
To increase awareness of immune-mediated chemotherapy side effects
Durvalumab is an immune checkpoint inhibitor (ICI) chemotherapeutic drug enhancing immune anti-cancer response by inhibiting PD-L1 and promoting T-cell activation. Paraneoplastic limbic encephalitis (LE) is a syndrome characterized by cross-reactive autoimmune response to the limbic structures usually preceding diagnosis of malignancy. Definitive treatment of LE is the treatment of cancer, however, interplay between immunotherapy used for cancer treatment and paraneoplastic conditions brings diagnostic and management challenges.
Not applicable
A 57-year-old woman with small cell lung cancer initially treated with cisplatin, etoposide, and radiation therapy was subsequently transitioned to Durvalumab. Three days after starting Durvalumab, she developed severe global aphasia. Brain MRI demonstrated restricted diffusion in the left posterior temporal lobe with cortical and subcortical T2/FLAIR hyperintensity and mild leptomeningeal enhancement. EEG showed near continuous lateralized rhythmic delta activity in the left hemisphere. Serum ANNA-1(Anti-Hu) antibodies titer was 1:30720. The patient was diagnosed with Anti-Hu antibody medicated LE. Durvalumab was discontinued. Improvement in reading, writing and word finding abilities was noted after a 5-day plasmapheresis. Follow up serum ANNA-1(Anti-Hu) titer was 1:256; EEG normalized; and MRI brain showed decreased left posterior temporal cortical swelling and FLAIR hyperintensity with decreased enhancement.
This is a first documented case of Durvalumab potentially inducing ANNA-1(Anti-Hu) mediated limbic encephalitis, likely due to the enhancing preexisting immune cells harboring ANNA-1(Anti-Hu) antibodies at baseline titers too low to induce clinical manifestations. This case suggests it may be helpful to obtain paraneoplastic panel prior to starting immune therapy for cancers, and to monitor patients for development of paraneoplastic syndromes while treating patients with Durvalumab.
Authors/Disclosures
Alex Cabe, DO (Stony Brook Medicine, Dept of Neurology)
PRESENTER 		Dr. Cabe has nothing to disclose.
Sarah Westlake, DO (Stony Brook Medicine, Dept of Neurology) Mrs. Westlake has nothing to disclose.
Olga Selioutski, DO The institution of Dr. Selioutski has received research support from NIH.
Patricia K. Coyle, MD, FAAN (SUNY At Stony Brook) Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant. Dr. Coyle has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Coyle has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Sanofi Genzyme. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GlaxoSmithKline. Dr. Coyle has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon Therapeutics. The institution of Dr. Coyle has received research support from CorEvitas LLC. The institution of Dr. Coyle has received research support from Genentech/Roche. The institution of Dr. Coyle has received research support from NINDS. The institution of Dr. Coyle has received research support from Sanofi Genzyme. The institution of Dr. Coyle has received research support from Cleveland Clinic.